Disclaimer

The information contained in this website is for general information purposes only. The information is provided by Gravity Capital and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.

  • 7F, NO. 1, Aly. 30, Ln. 358, Ruiguang RD., Neihu Dist., Taipei City 11492, Taiwan
  • +886-2-77201070
  • info@gravitycapital.com
  • Disclaimer

    The information contained in this website is for general information purposes only. The information is provided by Gravity Capital and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

    In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.

  • address:
    7F, NO. 1, Aly. 30, Ln. 358, Ruiguang RD., Neihu Dist., Taipei City 11492, Taiwan
  • tel:
    +886-2-77201070
  • email:
    info@gravitycapital.com
  • Celebrating Our Company’s “Human Septin 9 Gene Methylation Test Kit” Designated as a Jiangsu Province Key Research and Development Planning Project

    Release time: 2020-06-10Number of visits:422author:admin

    Recently, Jiangsu Provincial Science and technology department has unveiled its first batch of “2020 crucial provincial research and development projects”, Jiangsu MicroDiag’s Human Septi-9 gene methylation test kit (fluorescent PCR) successfully made it on the list, index number 124.

    MicroDiag’s Human Septin-9 gene methylation test kit uses 2nd generation methylation technology, methylation specific primer amplification, discarding the 1st generation technology often employed by MicroDiag’s competitors. This technology has drastically reduced the rate of false positives, increased the detection rate of Colorectal cancer, positive matching rate as high as 85% ~ 95%, specificity greater than 95%. This product has gained registration approve by Chinese NMPA in 2018: 20183400103, mainly used in early detection and diagnostics of Colorectal cancer, treatment monitoring and so on.

    Coming after this recognition as a crucial project by the Jiangsu Provincial government, we plan on collaborating with experts in the field and national key hospitals to commence a large-scale comparative study against Colonoscopy results, in order to establish the correlation between MicroDiag’s S9 test kit results and colonoscopy results, providing key insights for clinical diagnostics. 

    For over 10 years, MicroDiag has tirelessly dedicated to the research and development of molecular detection technology and high-quality innovative products, committing to contribute our unique strength for human health.